Embracing Mortality: The Strange Gift of Caregiving

For many of us, death has often been a distant and abstract concept—something that happens to other people, at other times, in other places. Our modern world, with its focus on youth and vitality, often pushes the reality of death to the margins of our consciousness. However, when we step into the role of caregivers for seniors and the terminally ill, we can no longer afford the luxury of denial. The presence of death becomes a daily reality, forcing us to confront our own mortality and that of those around us.

This confrontation with mortality offers us a choice: we can succumb to morbidity and depression, or we can choose a path of acceptance and growth. We can make friends with death.

(Note: About Us, a reference bibliography, related books and videos are all found at the end of this article.)

The Role of GLP-1 Drugs in Managing Type 2 Diabetes, Obesity and Dementia

Once a niche medication for managing type 2 diabetes, Ozempic has rapidly become a cultural phenomenon—celebrated for dramatic weight loss, criticized for contributing to drug shortages, and now attracting attention for a far more audacious possibility: could it help prevent Alzheimer’s disease? As media buzz collides with pharmaceutical marketing and genuine scientific curiosity, it’s worth asking: how much of this excitement is backed by evidence?

At the heart of the conversation are glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs that has fundamentally changed the treatment landscape for both diabetes and obesity. Semaglutide—sold as Ozempic—is among the most potent and promising. While its effectiveness in improving blood sugar control and reducing cardiovascular risk is well established, new research hints at broader effects, including potential neuroprotective benefits. This article examines the science, speculation, and reality behind one of the most widely discussed drugs in modern medicine.

(Note: About Us, a reference bibliography, related books and videos are all found at the end of this article.)